Johnson & Johnson (NYSE: JNJ) recently reported its Q3 results, with revenues and earnings exceeding our estimates.

On Tuesday, Johnson & Johnson (NYSE:JNJ) reported a third-quarter adjusted EPS of $2.42, down 9.0% year-over-year, beating ...

RBC Capital raised the firm’s price target on Johnson & Johnson to $181 from $178 and keeps an Outperform rating on the ...

The FDA’s Suzanne Schwartz said at The Medtech Conference that addressing legacy devices is a “work in progress” and a problem that regulators and industry need to work on together.

Here are eight key developments from spine and orthopedic devicemakers since Oct. 9. 1. Johnson & Johnson MedTech began the first phase of launching its Volt Variable Angle Optimized Locking ...

Johnson & Johnson first shared details on the Ottava surgical robotic platform nearly three years ago. At the time, the ...

Johnson & Johnson is cutting several programs—most of which are in neurology and psychiatry—as the company also pulls back ...

Artificial intelligence can revolutionize drug discovery by expediting development, reducing costs, and improving treatment ...

Merck KGaA lowered its medium-term outlook for its healthcare and life-science segment due to China challenges and recent pipeline setbacks but raised its electronics forecast, citing strong ...

The CIO50 Awards program celebrates the achievements of the top senior technology and digital executives in Australia who are ...

The Phase II cut in Alzheimer’s puts a question mark against the lofty heights J&J had envisaged for seltorexant. Less than a ...

India on Thursday weighed in on the ongoing diplomatic spat with Canada by holding the Trudeau administration responsible for 'precipitating' the current diplomatic fallout while acknowledging the ...